Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

被引：3

作者：

Yeung, David T. ^{[1
,2
]}

Mauro, Michael J. ^{[3
]}

机构：

[1] SA Pathol, Dept Haematol & Mol Pathol, Adelaide, SA, Australia

[2] Univ Adelaide, Sch Med, Discipline Med, Adelaide, SA, Australia

[3] Mem Sloan Kettering Canc Ctr, Myeloproliferat Neoplasms Program, New York, NY 10065 USA

来源：

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM | 2014年

基金：

英国医学研究理事会;

关键词：

BCR-ABL1 TRANSCRIPT LEVELS; FOLLOW-UP; IMATINIB; CML; PREDICT; DISCONTINUATION; RECOMMENDATIONS; DASATINIB; NILOTINIB; SURVIVAL;

D O I：

10.1182/asheducation-2014.1.240

中图分类号：

G40 [教育学];

学科分类号：

040101 ; 120403 ;

摘要：

A 55-year-old man presented with splenomegaly (10 cm below left costal margin) and leucocytosis (145 x 10(9)/L). Differential showed neutrophilia with increased basophils (2%), eosinophils (1.5%), and left shift including myeloblasts (3%). A diagnosis of chronic myeloid leukemia in chronic phase was established after marrow cytogenetics demonstrated the Philadelphia chromosome. Molecular studies showed a BCR-ABL1 qPCR result of 65% on the International Scale. Imatinib therapy at 400 mg daily was initiated due to patient preference, with achievement of complete hematological response after 4 weeks of therapy. BCR-ABL1 at 1 and 3 months after starting therapy was 37% and 13%, respectively (all reported on International Scale). Is this considered an adequate molecular response?

引用

页码：240 / 243

页数：4

共 50 条

[31] Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia [J].

Caldemeyer, Lauren ;

Dugan, Michael ;

Edwards, John ;

Akard, Luke .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2016, 11 (02) :71-79

[32] The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting [J].

Di Bella, Nicholas J. ;

Bhowmik, Debajyoti ;

Bhor, Menaka ;

Yap, Mark ;

Middlebrook, Brooke ;

Rembert, Debra ;

Cain, Zachary ;

Okoro, Tony ;

Bolinder, Bjorn ;

Patt, Debra ;

Jabbour, Elias J. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (10) :599-605

[33] A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors [J].

Zulbaran-Rojas, Alejandro ;

Lin, Huei-Kan ;

Shi, Qiuling ;

Williams, Loretta A. ;

George, Binsah ;

Garcia-Manero, Guillermo ;

Jabbour, Elias ;

O'Brien, Susan ;

Ravandi, Farhad ;

Wierda, William ;

Estrov, Zeev ;

Borthakur, Gautam ;

Kadia, Tapan ;

Cleeland, Charles ;

Cortes, Jorge E. ;

Kantarjian, Hagop .

CANCER MEDICINE, 2018, 7 (11) :5457-5469

[34] Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors [J].

Veltmaat, Lukas ;

Cortes, Jorge .

BLOOD, 2024, 143 (10) :858-865

[35] Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response [J].

Klil-Drori, Adi J. ;

Yin, Hui ;

Azoulay, Laurent ;

Harnois, Michael ;

Gratton, Michel-Olivier ;

Del Corpo, Alexa ;

Olney, Harold J. ;

Delage, Robert ;

Laneuville, Pierre ;

Mollica, Luigina ;

Busque, Lambert ;

Assouline, Sarit E. .

AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (10) :E602-E604

[36] Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors [J].

Breccia, Massimo ;

Alimena, Giuliana .

LEUKEMIA RESEARCH, 2013, 37 (06) :713-720

[37] Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia patients [J].

Yuki Osada ;

Hideki Arakaki ;

Satoshi Takanashi ;

Chisako Ito ;

Yoshinobu Aisa ;

Tomonori Nakazato .

Medical Oncology, 2017, 34

[38] Hodgkin Lymphoma in a Case of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors [J].

Gajendra, Smeeta ;

Sharma, Archana ;

Sharma, Rashi ;

Gupta, Sunil Kumar ;

Sood, Nitin ;

Sachdev, Ritesh .

TURKISH JOURNAL OF PATHOLOGY, 2019, 35 (01) :74-78

[39] EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience [J].

Jabbour, Elias ;

Cortes, Jorge ;

Nazha, Aziz ;

O'Brien, Susan ;

Quintas-Cardama, Alfonso ;

Pierce, Sherry ;

Garcia-Manero, Guillermo ;

Kantarjian, Hagop .

BLOOD, 2012, 119 (19) :4524-4526

[40] Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment [J].

Chelysheva, Ekaterina ;

Turkina, Anna ;

Polushkina, Evgenia ;

Shmakov, Roman ;

Zeifman, Alexey ;

Aleshin, Sergey ;

Shokhin, Igor ;

Guranda, Dorel ;

Oksenjuk, Oksana ;

Mordanov, Sergey ;

Kazakbaeva, Khamida ;

Chilov, Ghermes .

LEUKEMIA & LYMPHOMA, 2018, 59 (03) :733-738

← 1 2 3 4 5 →